Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | POLQ | O75417 | 4/20 | 0.36 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12436182 | 0.85 | NOTUM (0.46) | NOTUMTACR1P2RX1ACP1GPBAR1 | |
| SCHEMBL6815372 | 0.78 | NOTUM (0.43) | NOTUMTACR1P2RX1ACP1GPBAR1 | |
| SCHEMBL30503556 | 0.78 | NOTUM (0.43) | NOTUMTACR1P2RX1ACP1GPBAR1 | |
| SCHEMBL20568892 | 0.76 | NOTUM (0.46) | NOTUMTACR1P2RX1ACP1RXRA | |
| SCHEMBL28141847 | 0.75 | TP53 (0.50) | TACR1SMN1; SMN2MAPTPDK2CES2 | |
| SCHEMBL11006983 | 0.74 | TACR1 (0.57) | TACR1P2RX1MAPTRXRACES2 | |
| SCHEMBL7143432 | 0.74 | FSCN1 (0.36) | SMN1; SMN2MAPTPDK2 | |
| SCHEMBL1409680 | 0.73 | NOTUM (0.41) | NOTUMTACR1SMN1; SMN2P2RX1ACP1 | |
| SCHEMBL14438022 | 0.73 | SMN1; SMN2 (0.71) | SMN1; SMN2MAPTRXRANR1H2NR1H3 | |
| SCHEMBL15397669 | 0.73 | TACR1 (0.59) | TACR1P2RX1MAPTRXRACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295406-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | NOTUM 874/4885TACR1 174/4885SMN1; SMN2 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.